IL173136A0 - Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases - Google Patents
Pyrazolines as par-1 antagonists for treatment of cardiovascular diseasesInfo
- Publication number
- IL173136A0 IL173136A0 IL173136A IL17313606A IL173136A0 IL 173136 A0 IL173136 A0 IL 173136A0 IL 173136 A IL173136 A IL 173136A IL 17313606 A IL17313606 A IL 17313606A IL 173136 A0 IL173136 A0 IL 173136A0
- Authority
- IL
- Israel
- Prior art keywords
- pyrazolines
- par
- antagonists
- treatment
- cardiovascular diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10331951 | 2003-07-15 | ||
DE102004010545A DE102004010545A1 (en) | 2003-07-15 | 2004-03-04 | pyrazolines |
PCT/EP2004/007227 WO2005007157A1 (en) | 2003-07-15 | 2004-07-02 | Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL173136A0 true IL173136A0 (en) | 2006-06-11 |
Family
ID=34088638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL173136A IL173136A0 (en) | 2003-07-15 | 2006-01-12 | Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN1852710A (en) |
DE (1) | DE102004010545A1 (en) |
EC (1) | ECSP066281A (en) |
IL (1) | IL173136A0 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104086501B (en) * | 2014-07-23 | 2016-02-17 | 张远强 | A kind of PAR-1 antagonist, Preparation Method And The Use |
CN111892585A (en) * | 2020-08-05 | 2020-11-06 | 杭州维坦医药科技有限公司 | N-formamido pyrazoline derivative as P2X3 receptor antagonist and application thereof |
-
2004
- 2004-03-04 DE DE102004010545A patent/DE102004010545A1/en not_active Withdrawn
- 2004-07-02 CN CNA2004800265401A patent/CN1852710A/en active Pending
-
2006
- 2006-01-12 EC EC2006006281A patent/ECSP066281A/en unknown
- 2006-01-12 IL IL173136A patent/IL173136A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE102004010545A1 (en) | 2005-02-24 |
ECSP066281A (en) | 2006-07-28 |
CN1852710A (en) | 2006-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL174014A0 (en) | Methods for the treatment of endometriosis | |
IL156495A0 (en) | Use of fgfr3 antagonists for treating t cell mediated diseases | |
IL169332A0 (en) | Compounds for the treatment of metabolic disorders | |
EP1638508A4 (en) | Shunt for the treatment of glaucoma | |
EP1789086A4 (en) | Extended treatment of multiple sclerosis | |
EP1745573A4 (en) | Methods of manufacture of 2 -deoxy- beta-l-nucleosides | |
IL175535A0 (en) | Compositions for treatment of neurodegenerative diseases | |
GB0324761D0 (en) | Use of compounds in therapy | |
GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
EP1680145A4 (en) | Methods and compositions for the treatment of neurological disease | |
GB0305150D0 (en) | Use of therapeutic compounds | |
EP1611120A4 (en) | Novel methods for the treatment of inflammatory diseases | |
IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
TWI367753B (en) | Composition for normalization of infradian rhythm | |
EP1709155A4 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
EP1667827A4 (en) | Process for the treatment of wood | |
IL173136A0 (en) | Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases | |
PL1687006T3 (en) | Pharmaceutical compositions for the treatment of renal dysfunction | |
GB0426196D0 (en) | Methods of treatment | |
GB0313630D0 (en) | Compositions for the enhanced treatment of depression | |
ZA200606780B (en) | Compounds for the treatment of diseases | |
AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
GB0327975D0 (en) | Methods of treatment | |
GB0313801D0 (en) | Novel methods of treatment | |
GB0322921D0 (en) | Methods of treatment |